{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-23-000010","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.604639+00:00","generated_at":"2026-06-15T22:03:14.818596+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia Q1 net revenue $34.4M (+59% YoY); raises 2023 revenue guidance to $135-155M","bullets":["Net product revenue $34.3M, up from $21.5M in Q1 2022; net loss $26.2M ($0.18/share) vs $37.6M loss a year ago.","Raised FY 2023 LUPKYNIS net product revenue guidance to $135-155M, from prior $120-140M.","1,731 patients on LUPKYNIS therapy at March 31, 2023, up from 1,071 a year earlier; 466 PSFs added in Q1.","New method-of-use patent issued; NICE positive recommendation for LUPKYNIS in UK; Swiss regulatory approval received.","Cash and short-term investments $361.5M at quarter end vs $389.4M at Dec 31, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-23-000010","json":"https://secwatch.observer/filing/0001600620-23-000010.json","markdown":"https://secwatch.observer/filing/0001600620-23-000010.md","text":"https://secwatch.observer/filing/0001600620-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/0001600620-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/auph-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:03:14.818596+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b5062a32b60990433fd7dd92c50f5f00d34cb1a","claim":"Aurinia Pharmaceuticals Inc. reported first quarter ended March 31, 2023 results: revenue $34.4 million, net income $26.2 million or $0.18 net loss per common share, EPS $0.18 net loss per common share. Guidance raised.","evidence_excerpt":"as expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATIONAL RESULTS $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062023000010/0001600620-23-000010-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Revenue","value":"$34.4 million"},{"label":"Net income","value":"$26.2 million or $0.18 net loss per common share"},{"label":"EPS","value":"$0.18 net loss per common share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}